HIV/AIDS

Generic PrEP Receives FDA Approval

The first generic version of the HIV drug Truvada has received approval from the Food and Drug Administration.
The drug is approved for the “treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually acquired HIV infection in adults at high risk,” said a statement from the FDA.
Common side effects among HIV-1 infected people taking the generic PrEP in clinical trials included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams and rash. HIV-free people taking Truvada for PrEP reported headache, abdominal pain and weight loss.
When the generic form is used to prevent HIV infection, it “must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initial use and periodically during use,” the FDA said.
The agency also gave this recommendation: Women with HIV-1 shouldn’t breastfeed while taking the medication.

Related:
ProActive Health: 4th Black Health Matters Summit

Related posts

Community-Building Leads to Record Enrollment in HIV Prevention Study

rdanielsr6d7

STDs Up Among Young African Americans

rdanielsr6d7

Young and Positive

rdanielsr6d7